 Connection
Arnon Haran to Neoplasm, Residual
This is a "connection" page, showing publications Arnon Haran has written about Neoplasm, Residual.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.163 |
|
|
|
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
Score: 0.057
-
Nachmias B, Haran A, Yisraeli Salman M, Stein EM. Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights. Br J Haematol. 2025 Oct; 207(4):1192-1212.
Score: 0.054
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|